INC Research to oversee Ph II trial for Cellectar Biosciences

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/BernardaSv)
(Image: iStock/BernardaSv)

Related tags: Clinical trial

Cellectar Biosciences has announced INC Research as its contract research organization (CRO) for the company’s Phase II trial of CLR 131 in hematologic malignancies.

A $2m grant from the National Cancer Institute (NCI) will cover half the study cost, with the potential option to pursue another $3m for a pivotal Phase III trial of Cellectar’s lead radiotherapeutic compound.

According to the company, the results of the 80-patient, Phase II study will be used to design its pivotal trial of CLR 131 in multiple myeloma and other hematologic malignancies.

Jim Caruso, president and CEO of Cellectar described INC Research as the “ideal partner for this important trial​.”

The company expects to initiate the trial during the first quarter of 2017.

As many as 15 participating sites will be used in order to provide initial efficacy data in the second half of 2017.

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

show more

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us

Products

View more

Webinars